481 related articles for article (PubMed ID: 33180231)
21. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Liguori G; Trombetta C; De Giorgi G; Pomara G; Maio G; Vecchio D; Ocello G; Ollandini G; Bucci S; Belgrano E
J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
[TBL] [Abstract][Full Text] [Related]
24. Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study.
Márquez PHP; Torres OH; San-José A; Vidal X; Agustí A; Formiga F; López-Soto A; Ramírez-Duque N; Fernández-Moyano A; Garcia-Moreno J; Arroyo JA; Ruiz D;
Drugs Aging; 2017 Jun; 34(6):453-466. PubMed ID: 28432600
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
[TBL] [Abstract][Full Text] [Related]
26. Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?
Prasetyo DT; Raharja PAR; Mantiri BJ; Ringoringo DRL; Rahman IA; Felizio J; Tambunan MP; Fadhly SF; Rahardjo HE
Acta Med Indones; 2019 Jul; 51(3):275-281. PubMed ID: 31699953
[TBL] [Abstract][Full Text] [Related]
27. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular drugs and erectile dysfunction - a symmetry analysis.
Rasmussen L; Hallas J; Madsen KG; Pottegård A
Br J Clin Pharmacol; 2015 Nov; 80(5):1219-23. PubMed ID: 26094913
[TBL] [Abstract][Full Text] [Related]
29. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
Costa P; Buvat J; Holmes S; Weitckus S; Petto H; Hamidi K; Varanese L
J Sex Med; 2006 Nov; 3(6):1050-1058. PubMed ID: 17100938
[TBL] [Abstract][Full Text] [Related]
30. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
31. Chinese herbal medicine combined with tadalafil for erectile dysfunction: a systematic review and meta-analysis.
Wang YL; Geng LG; He CB; Yuan SY
Andrology; 2020 Mar; 8(2):268-276. PubMed ID: 31464074
[TBL] [Abstract][Full Text] [Related]
32. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
[TBL] [Abstract][Full Text] [Related]
33. Sexual history taking and sexually transmitted infection screening in patients initiating erectile dysfunction medication therapy.
Holman KM; Carr JA; Baddley JW; Hook EW
Sex Transm Dis; 2013 Nov; 40(11):836-8. PubMed ID: 24113402
[TBL] [Abstract][Full Text] [Related]
34. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.
Incrocci L; Slagter C; Slob AK; Hop WC
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):439-44. PubMed ID: 16965992
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.
Buvat J; van Ahlen H; Schmitt H; Chan M; Kuepfer C; Varanese L
J Sex Med; 2006 May; 3(3):512-20. PubMed ID: 16681477
[TBL] [Abstract][Full Text] [Related]
37. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.
Buvat J; Hatzichristou D; Boess FG; Büttner H; Gehchan N; Henneges C; Porst H
Int J Clin Pract; 2014 Sep; 68(9):1087-99. PubMed ID: 25123817
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk.
Nehra A; Jackson G; Miner M; Billups KL; Burnett AL; Buvat J; Carson CC; Cunningham GR; Goldstein I; Guay AT; Hackett G; Kloner RA; Kostis J; Montorsi P; Ramsey M; Rosen RC; Sadovsky R; Seftel AD; Vlachopoulos C; Wu FC
J Urol; 2013 Jun; 189(6):2031-8. PubMed ID: 23313195
[TBL] [Abstract][Full Text] [Related]
39. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Iannino-Renz R; Mager D
Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
[TBL] [Abstract][Full Text] [Related]
40. [Safety of tadalafil in patients with cardiovascular comorbidities].
Nikitina IL; Gaysina GG; Galimov SN; Bulygin KV; Galimova EF; Pavlov VN
Urologiia; 2019 Apr; (1):119-124. PubMed ID: 31184029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
